SteadyMed

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch SteadyMed and buy or sell other stocks, ETFs, and their options commission-free!

About STDY

SteadyMed Ltd. was engaged in the research, development, and manufacture of pharmaceutical products through the PatchPump technology. Its portfolio included Trevyent for pulmonary arterial hypertension and At Home Patient Analgesia for post-surgical pains. 

CEO
Jonathan M. N. Rigby, MBA
CEOJonathan M. N. Rigby, MBA
Employees
Employees
Headquarters
Rehovot, Tel Aviv
HeadquartersRehovot, Tel Aviv
Founded
2005
Founded2005
Employees
Employees

STDY Key Statistics

Market cap
126.36M
Market cap126.36M
Price-Earnings ratio
-4.69
Price-Earnings ratio-4.69
Dividend yield
Dividend yield
Average volume
127.77K
Average volume127.77K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$4.80
52 Week high$4.80
52 Week low
$2.60
52 Week low$2.60

Stock Snapshot

With a market cap of 126.36M, SteadyMed(STDY) trades at $4.75. The stock has a price-to-earnings ratio of -4.69.

On 2026-07-25, SteadyMed(STDY) stock opened at —, reached a high of —, and a low of —.

SteadyMed(STDY) shares are trading with a volume of 0, against a daily average of 127.77K.

During the past year, SteadyMed(STDY) stock moved between $2.60 at its lowest and $4.80 at its peak.

During the past year, SteadyMed(STDY) stock moved between $2.60 at its lowest and $4.80 at its peak.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.